Bing Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bing Xu has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Ying Xiao
Shenyang First People’s Hospital, Shenyang, China
10 shared publicationsHaoyue Zhu
Shenyang Tenth People’s Hospital (Shenyang Chest Hospital), Shenyang, China
8 shared publications- Yi Sui
Department of Neurology, The Fourth People’s Hospital of Shenyang, China Medical University (Y.S.).
8 shared publications Miaoran Wang
China Medical University, shenyang, China
7 shared publicationsQian He
Qionglai Traditional Chinese Medicine Hospital, Chengdu, China
7 shared publicationsRui Wen
Shenyang Tenth People’s Hospital (Shenyang Chest Hospital), Shenyang, China
7 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1878389
An AI-driven model for risk stratification and prototype intervention mapping in motoric cognitive risk syndrome and subjective cognitive decline
As Alzheimer's disease and other dementias continue their global rise, there is a compelling need for early identification of pre-clinical cognitive decline. Motoric Cognitive Risk Syndrome and Subjective Cognitive Decline represent crucial transition phases to facilitate targeted intervention, and existing unimodal approaches are neither sensitive nor sufficiently multimodal for appropriate risk classification and individualized intervention mapping (prototype). This study introduces a hybrid multimodal CNN fusion framework based on an improved version of light spectrum optimizer as metaheuristic optimizer to address this challenge. The framework fuses multiple modality-specific information through parallel three-dimensional convolutional neural network branches (MRI and PET) and encoders of motor, cognitive, and biomarker information followed by a combination of intermediate and late fusion layers with parameters tuned by the optimized framework. The framework is meticulously assessed on the BIOCARD longitudinally dataset and achieved an accuracy of 93.7% and an area under the ROC curve (AUC) of 0.965. It significantly surpassed seven state-of-the-art methods and revealed clinical interpretability through longitudinal risk trajectories and SHAP attribution of features.
- 23 October 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1878389
Open AccessAn AI-driven model for risk stratification and prototype intervention mapping in motoric cognitive risk syndrome and subjective cognitive decline
As Alzheimer's disease and other dementias continue their global rise, there is a compelling need for early identification of pre-clinical cognitive decline. Motoric Cognitive Risk Syndrome and Subjective Cognitive Decline represent crucial transition phases to facilitate targeted intervention, and existing unimodal approaches are neither sensitive nor sufficiently multimodal for appropriate risk classification and individualized intervention mapping (prototype). This study introduces a hybrid multimodal CNN fusion framework based on an improved version of light spectrum optimizer as metaheuristic optimizer to address this challenge. The framework fuses multiple modality-specific information through parallel three-dimensional convolutional neural network branches (MRI and PET) and encoders of motor, cognitive, and biomarker information followed by a combination of intermediate and late fusion layers with parameters tuned by the optimized framework. The framework is meticulously assessed on the BIOCARD longitudinally dataset and achieved an accuracy of 93.7% and an area under the ROC curve (AUC) of 0.965. It significantly surpassed seven state-of-the-art methods and revealed clinical interpretability through longitudinal risk trajectories and SHAP attribution of features.
- Open Access
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1967401
Zonula occludens-1 at the ischemic blood–brain barrier: mechanisms of disruption, functional significance, and experimental modulation
Blood–brain barrier (BBB) disruption is a major component of ischemic brain injury, yet the contribution of zonula occludens-1 (ZO-1) is often inferred from changes in total protein abundance. Here we synthesize evidence showing that ZO-1 is instead a dynamically regulated junctional scaffold whose disruption encompasses mechanistically distinct states. Ischemia and reperfusion alter ZO-1 through caveolin-dependent internalization and endolysosomal degradation, phosphorylation and cytoskeletal redistribution, transcriptional and epigenetic regulation, and convergent oxidative, inflammatory, metabolic and multicellular signaling. These mechanisms can impair junctional continuity and paracellular barrier function without necessarily reducing total ZO-1. Conversely, BBB permeability can improve without proportional recovery of ZO-1 abundance, reflecting contributions from transcellular transport, the basal lamina and other neurovascular components. Numerous interventions preserve or restore ZO-1 alongside reduced leakage, edema or hemorrhagic transformation, but most act on upstream injury pathways and do not establish that ZO-1 is necessary for barrier rescue. We therefore propose that ZO-1 should be interpreted as a mechanistically informative readout of endothelial junctional integrity rather than a universal surrogate for BBB recovery or a validated therapeutic target. The available evidence remains predominantly preclinical, while limited clinical studies have evaluated circulating ZO-1 and other tight-junction proteins as biomarkers rather than directly assessing endothelial junctional ZO-1 in the ischemic brain. Translation will therefore require confirmation of ZO-1 molecular states and causal relevance in human BBB systems and patient-level studies, together with clinically relevant reperfusion, comorbidity, and treatment-window paradigms.
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1967401
Open AccessZonula occludens-1 at the ischemic blood–brain barrier: mechanisms of disruption, functional significance, and experimental modulation
Blood–brain barrier (BBB) disruption is a major component of ischemic brain injury, yet the contribution of zonula occludens-1 (ZO-1) is often inferred from changes in total protein abundance. Here we synthesize evidence showing that ZO-1 is instead a dynamically regulated junctional scaffold whose disruption encompasses mechanistically distinct states. Ischemia and reperfusion alter ZO-1 through caveolin-dependent internalization and endolysosomal degradation, phosphorylation and cytoskeletal redistribution, transcriptional and epigenetic regulation, and convergent oxidative, inflammatory, metabolic and multicellular signaling. These mechanisms can impair junctional continuity and paracellular barrier function without necessarily reducing total ZO-1. Conversely, BBB permeability can improve without proportional recovery of ZO-1 abundance, reflecting contributions from transcellular transport, the basal lamina and other neurovascular components. Numerous interventions preserve or restore ZO-1 alongside reduced leakage, edema or hemorrhagic transformation, but most act on upstream injury pathways and do not establish that ZO-1 is necessary for barrier rescue. We therefore propose that ZO-1 should be interpreted as a mechanistically informative readout of endothelial junctional integrity rather than a universal surrogate for BBB recovery or a validated therapeutic target. The available evidence remains predominantly preclinical, while limited clinical studies have evaluated circulating ZO-1 and other tight-junction proteins as biomarkers rather than directly assessing endothelial junctional ZO-1 in the ischemic brain. Translation will therefore require confirmation of ZO-1 molecular states and causal relevance in human BBB systems and patient-level studies, together with clinically relevant reperfusion, comorbidity, and treatment-window paradigms.
- Open Access
- 30 January 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1487248
Nomogram to predict 3 month prognosis of acute ischemic stroke among young adults
Objective: This study aimed to develop and validate a nomogram for predicting the risk of 3 months adverse outcomes among young adults with acute ischemic stroke (AIS).Methods: Patients aged between 18 and 50 with acute ischemic stroke (AIS) at the Shenyang First’s People Hospital, between January 1st 2017 to May 30th 2023 were included in this retrospective study. The primary outcome was a three-month unfavorable outcome, evaluated with modified Rankin Scale (mRS > 2). Univariate logistic regression was used to select the independent factors of prognosis and multivariate logistic regression to establish a new nomogram model. We used the area under the receiver-operating characteristic curve (ROC) to evaluate the discriminative performance and used the calibration curve with Hosmer-Lemeshow goodness of fit test to assess the calibration performance of the risk prediction model. Decision curve analysis (DCA) was applied to assess the clinical utility of the nomogram.Results: A total of 1,015 patients were enrolled. Gender (male vs. female; Odds ratio[OR], 0.5562[95% Confidence Interval (CI), 0.3104–1.0478]; p = 0.053), family history of stroke (OR, 3.5698[95%CI 1.5632–8.0329], p < 0.001), prior stroke (OR, 2.1509[95%CI 1.2610–3.6577], p < 0.001), previous heart disease (OR, 3.4047[95%CI, 1.7838–6.6976], p < 0.01) toast type (cardio-embolism stroke vs. large-artery atherosclerosis (LAA), OR, 0.0847[0.0043–0.5284], p < 0.01), toast type (stroke of undetermined etiology vs. LAA, OR, 0.0847[0.0439–0.5284], p < 0.01), mRS at admission (OR, 15.2446 [9.1447–26.3156], p < 0.0001), adherence to medication (OR, 2.1197[95%CI, 1.1924–3.7464], p < 0.001), systolic blood pressure (SBP; OR, 1.0145[1.0041–1.0250], p < 0.001), and lactate dehydrogenase (LDH; OR, 1.0060[1.0010–1.0111], p < 0.01) were related to 3 months adverse outcomes among young adults with AIS. The nomogram displayed excellent calibration and discrimination. DCA confirmed the clinical applicability of the model.Conclusion: The nomogram comprised of gender, family history of stroke, prior stroke, previous heart disease, toast type, mRS score at admission, adherence to medication, SBP and LDH may predict 3 months adverse outcomes among young adults with AIS.
- 30 January 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1487248
Open AccessNomogram to predict 3 month prognosis of acute ischemic stroke among young adults
Objective: This study aimed to develop and validate a nomogram for predicting the risk of 3 months adverse outcomes among young adults with acute ischemic stroke (AIS).Methods: Patients aged between 18 and 50 with acute ischemic stroke (AIS) at the Shenyang First’s People Hospital, between January 1st 2017 to May 30th 2023 were included in this retrospective study. The primary outcome was a three-month unfavorable outcome, evaluated with modified Rankin Scale (mRS > 2). Univariate logistic regression was used to select the independent factors of prognosis and multivariate logistic regression to establish a new nomogram model. We used the area under the receiver-operating characteristic curve (ROC) to evaluate the discriminative performance and used the calibration curve with Hosmer-Lemeshow goodness of fit test to assess the calibration performance of the risk prediction model. Decision curve analysis (DCA) was applied to assess the clinical utility of the nomogram.Results: A total of 1,015 patients were enrolled. Gender (male vs. female; Odds ratio[OR], 0.5562[95% Confidence Interval (CI), 0.3104–1.0478]; p = 0.053), family history of stroke (OR, 3.5698[95%CI 1.5632–8.0329], p < 0.001), prior stroke (OR, 2.1509[95%CI 1.2610–3.6577], p < 0.001), previous heart disease (OR, 3.4047[95%CI, 1.7838–6.6976], p < 0.01) toast type (cardio-embolism stroke vs. large-artery atherosclerosis (LAA), OR, 0.0847[0.0043–0.5284], p < 0.01), toast type (stroke of undetermined etiology vs. LAA, OR, 0.0847[0.0439–0.5284], p < 0.01), mRS at admission (OR, 15.2446 [9.1447–26.3156], p < 0.0001), adherence to medication (OR, 2.1197[95%CI, 1.1924–3.7464], p < 0.001), systolic blood pressure (SBP; OR, 1.0145[1.0041–1.0250], p < 0.001), and lactate dehydrogenase (LDH; OR, 1.0060[1.0010–1.0111], p < 0.01) were related to 3 months adverse outcomes among young adults with AIS. The nomogram displayed excellent calibration and discrimination. DCA confirmed the clinical applicability of the model.Conclusion: The nomogram comprised of gender, family history of stroke, prior stroke, previous heart disease, toast type, mRS score at admission, adherence to medication, SBP and LDH may predict 3 months adverse outcomes among young adults with AIS.
- Open Access
- 27 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1506771
Following intravenous thrombolysis, the outcome of diabetes mellitus associated with acute ischemic stroke was predicted via machine learning
This cohort study aimed to evaluate the prognostic outcomes of patients with acute ischemic stroke (AIS) and diabetes mellitus following intravenous thrombolysis, utilizing machine learning techniques. The analysis was conducted using data from Shenyang First People’s Hospital, involving 3,478 AIS patients with diabetes who received thrombolytic therapy from January 2018 to December 2023, ultimately focusing on 1,314 patients after screening. The primary outcome measured was the 90-day Modified Rankin Scale (MRS). An 80/20 train-test split was implemented for model development and validation, employing various machine learning classifiers, including artificial neural networks (ANN), random forest (RF), XGBoost (XGB), and LASSO regression. Results indicated that the average accuracy of the XGB model was 0.7355 (±0.0307), outperforming the other models. Key predictors for prognosis post-thrombolysis included the National Institutes of Health Stroke Scale (NIHSS) and blood platelet count. The findings underscore the effectiveness of machine learning algorithms, particularly XGB, in predicting functional outcomes in diabetic AIS patients, providing clinicians with a valuable tool for treatment planning and improving patient outcome predictions based on receiver operating characteristic (ROC) analysis and accuracy assessments.
- 27 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1506771
Open AccessFollowing intravenous thrombolysis, the outcome of diabetes mellitus associated with acute ischemic stroke was predicted via machine learning
This cohort study aimed to evaluate the prognostic outcomes of patients with acute ischemic stroke (AIS) and diabetes mellitus following intravenous thrombolysis, utilizing machine learning techniques. The analysis was conducted using data from Shenyang First People’s Hospital, involving 3,478 AIS patients with diabetes who received thrombolytic therapy from January 2018 to December 2023, ultimately focusing on 1,314 patients after screening. The primary outcome measured was the 90-day Modified Rankin Scale (MRS). An 80/20 train-test split was implemented for model development and validation, employing various machine learning classifiers, including artificial neural networks (ANN), random forest (RF), XGBoost (XGB), and LASSO regression. Results indicated that the average accuracy of the XGB model was 0.7355 (±0.0307), outperforming the other models. Key predictors for prognosis post-thrombolysis included the National Institutes of Health Stroke Scale (NIHSS) and blood platelet count. The findings underscore the effectiveness of machine learning algorithms, particularly XGB, in predicting functional outcomes in diabetic AIS patients, providing clinicians with a valuable tool for treatment planning and improving patient outcome predictions based on receiver operating characteristic (ROC) analysis and accuracy assessments.
- Open Access
- 9 September 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1408457
Machine learning-based prediction of early neurological deterioration after intravenous thrombolysis for stroke: insights from a large multicenter study
Background: This investigation seeks to ascertain the efficacy of various machine learning models in forecasting early neurological deterioration (END) following thrombolysis in patients with acute ischemic stroke (AIS).Methods: Employing data from the Shenyang Stroke Emergency Map database, this multicenter study compiled information on 7,570 AIS patients from 29 comprehensive hospitals who received thrombolytic therapy between January 2019 and December 2021. An independent testing cohort was constituted from 2,046 patients at the First People’s Hospital of Shenyang. The dataset incorporated 15 pertinent clinical and therapeutic variables. The principal outcome assessed was the occurrence of END post-thrombolysis. Model development was executed using an 80/20 split for training and internal validation, employing classifiers like logistic regression with lasso regularization (lasso regression), support vector machine (SVM), random forest (RF), gradient-boosted decision tree (GBDT), and multi-layer perceptron (MLP). The model with the highest area under the curve (AUC) was utilized to delineate feature significance.Results: Baseline characteristics showed variability in END incidence between the training (n = 7,570; END incidence 22%) and external validation cohorts (n = 2,046; END incidence 10%; p < 0.001). Notably, all machine learning models demonstrated superior AUC values compared to the reference model, indicating their enhanced predictive capacity. The lasso regression model achieved the highest AUC at 0.829 (95% CI: 0.799–0.86; p < 0.001), closely followed by the MLP model with an AUC of 0.828 (95% CI: 0.799–0.858; p < 0.001). The SVM, RF, and GBDT models also showed commendable AUCs of 0.753, 0.797, and 0.774, respectively. Decision curve analysis revealed that the SVM and MLP models demonstrated a high net benefit. Feature importance analysis emphasized “Onset To Needle Time” and “Admission NIHSS Score” as significant predictors.Conclusion: Our research establishes the MLP and lasso regression as robust tools for predicting early neurological deterioration in acute ischemic stroke patients following thrombolysis. Their superior predictive accuracy, compared to traditional models, highlights the significant potential of machine learning approaches in refining prognosis and enhancing clinical decisions in stroke care management. This advancement paves the way for more tailored therapeutic strategies, ultimately aiming to improve patient outcomes in clinical practice.
- 9 September 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1408457
Open AccessMachine learning-based prediction of early neurological deterioration after intravenous thrombolysis for stroke: insights from a large multicenter study
Background: This investigation seeks to ascertain the efficacy of various machine learning models in forecasting early neurological deterioration (END) following thrombolysis in patients with acute ischemic stroke (AIS).Methods: Employing data from the Shenyang Stroke Emergency Map database, this multicenter study compiled information on 7,570 AIS patients from 29 comprehensive hospitals who received thrombolytic therapy between January 2019 and December 2021. An independent testing cohort was constituted from 2,046 patients at the First People’s Hospital of Shenyang. The dataset incorporated 15 pertinent clinical and therapeutic variables. The principal outcome assessed was the occurrence of END post-thrombolysis. Model development was executed using an 80/20 split for training and internal validation, employing classifiers like logistic regression with lasso regularization (lasso regression), support vector machine (SVM), random forest (RF), gradient-boosted decision tree (GBDT), and multi-layer perceptron (MLP). The model with the highest area under the curve (AUC) was utilized to delineate feature significance.Results: Baseline characteristics showed variability in END incidence between the training (n = 7,570; END incidence 22%) and external validation cohorts (n = 2,046; END incidence 10%; p < 0.001). Notably, all machine learning models demonstrated superior AUC values compared to the reference model, indicating their enhanced predictive capacity. The lasso regression model achieved the highest AUC at 0.829 (95% CI: 0.799–0.86; p < 0.001), closely followed by the MLP model with an AUC of 0.828 (95% CI: 0.799–0.858; p < 0.001). The SVM, RF, and GBDT models also showed commendable AUCs of 0.753, 0.797, and 0.774, respectively. Decision curve analysis revealed that the SVM and MLP models demonstrated a high net benefit. Feature importance analysis emphasized “Onset To Needle Time” and “Admission NIHSS Score” as significant predictors.Conclusion: Our research establishes the MLP and lasso regression as robust tools for predicting early neurological deterioration in acute ischemic stroke patients following thrombolysis. Their superior predictive accuracy, compared to traditional models, highlights the significant potential of machine learning approaches in refining prognosis and enhancing clinical decisions in stroke care management. This advancement paves the way for more tailored therapeutic strategies, ultimately aiming to improve patient outcomes in clinical practice.
- Open Access
- 30 August 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1450863
Mediation effect of stroke recurrence in the association between post-stroke lactate dehydrogenase and functional disability
Background: We aimed to use lactate dehydrogenase (LDH) as a marker of inflammation burden and quantify post-stroke inflammation’s direct and indirect effect on functional disability.Methods: We analyzed 5,129 patients with acute ischemic stroke (AIS) admitted to Shenyang First People’s Hospital. Stroke recurrence and functional outcome measured by the modified Rankin Scale (mRS) were assessed at 90 days. Functional disability was defined as mRS score > 2. Receiver operating characteristic curve and restricted cubic spline (RCS) analysis were conducted to illustrate the associations between LDH levels and 90-day functional outcomes in patients with AIS. Mediation analyses were performed to examine the potential causal chain in which stroke recurrence may mediate the relationship between LDH and functional outcome. Positive correlation between LDH and hs-CRP was found and mediation effects of stroke recurrence in the association between LDH or hs-CRP and functional disability were both less than 20%. Sensitivity analyses in different subgroups showed comparable results.Results: Among 5,129 included AIS patients, the median (IQR) level of LDH was 186 (161–204.4) U/L. Functional disability was seen in 1200 (23.4%) patients and recurrence was observed in 371(7.2%) patients at 90-day follow-up. Each standard deviation increase in the concentration of LDH was linked to an increased risk of functional disability (adjusted odds ratio[aOR], 1.07; 95%CI,1.04–1.09) and stroke recurrence (aOR,1.02; 95%CI, 1.01–1.04) within 90 days. The highest quartile of LDH (>204.2 U/L) had an elevated risk of suffering functional disability (aOR, 1.21; 95%CI, 1.00–1.47) and recurrence (aOR, 1.21; 95%CI,1.00–1.47) compared with the lowest quartile of LDH (<161 U/L). Stroke recurrence during follow-up explained 12.90% (95%CI, 6.22–21.16%) of the relationship between LDH and functional disability. Positive correlation between LDH and hs-CRP was found and mediation effects of recurrence in the association between LDH or hs-CRP and functional disability were both less than 20%. Sensitivity analyses in different subgroups showed comparable results.Conclusion: The relationship between LDH and functional disability at 90 days among AIS patients is partially mediated by stroke recurrence, accounting for less than 20%. LDH deserves equal attention as hs-CRP in predicting recurrence and functional outcome. In addition to traditional secondary prevention measures, innovative anti-inflammatory strategies warrant further investigation.
- 30 August 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1450863
Open AccessMediation effect of stroke recurrence in the association between post-stroke lactate dehydrogenase and functional disability
Background: We aimed to use lactate dehydrogenase (LDH) as a marker of inflammation burden and quantify post-stroke inflammation’s direct and indirect effect on functional disability.Methods: We analyzed 5,129 patients with acute ischemic stroke (AIS) admitted to Shenyang First People’s Hospital. Stroke recurrence and functional outcome measured by the modified Rankin Scale (mRS) were assessed at 90 days. Functional disability was defined as mRS score > 2. Receiver operating characteristic curve and restricted cubic spline (RCS) analysis were conducted to illustrate the associations between LDH levels and 90-day functional outcomes in patients with AIS. Mediation analyses were performed to examine the potential causal chain in which stroke recurrence may mediate the relationship between LDH and functional outcome. Positive correlation between LDH and hs-CRP was found and mediation effects of stroke recurrence in the association between LDH or hs-CRP and functional disability were both less than 20%. Sensitivity analyses in different subgroups showed comparable results.Results: Among 5,129 included AIS patients, the median (IQR) level of LDH was 186 (161–204.4) U/L. Functional disability was seen in 1200 (23.4%) patients and recurrence was observed in 371(7.2%) patients at 90-day follow-up. Each standard deviation increase in the concentration of LDH was linked to an increased risk of functional disability (adjusted odds ratio[aOR], 1.07; 95%CI,1.04–1.09) and stroke recurrence (aOR,1.02; 95%CI, 1.01–1.04) within 90 days. The highest quartile of LDH (>204.2 U/L) had an elevated risk of suffering functional disability (aOR, 1.21; 95%CI, 1.00–1.47) and recurrence (aOR, 1.21; 95%CI,1.00–1.47) compared with the lowest quartile of LDH (<161 U/L). Stroke recurrence during follow-up explained 12.90% (95%CI, 6.22–21.16%) of the relationship between LDH and functional disability. Positive correlation between LDH and hs-CRP was found and mediation effects of recurrence in the association between LDH or hs-CRP and functional disability were both less than 20%. Sensitivity analyses in different subgroups showed comparable results.Conclusion: The relationship between LDH and functional disability at 90 days among AIS patients is partially mediated by stroke recurrence, accounting for less than 20%. LDH deserves equal attention as hs-CRP in predicting recurrence and functional outcome. In addition to traditional secondary prevention measures, innovative anti-inflammatory strategies warrant further investigation.
- Open Access
- 18 April 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1364952
Effectiveness of the acute stroke care map program in reducing in-hospital delay for acute ischemic stroke in a Chinese urban area: an interrupted time series analysis
Background: Timely intravenous thrombolysis (IVT) is crucial for improving outcomes in acute ischemic stroke (AIS) patients. This study evaluates the effectiveness of the Acute Stroke Care Map (ASCaM) initiative in Shenyang, aimed at reducing door-to-needle times (DNT) and thus improving the timeliness of care for AIS patients.Methods: An retrospective cohort study was conducted from April 2019 to December 2021 in 30 hospitals participating in the ASCaM initiative in Shenyang. The ASCaM bundle included strategies such as EMS prenotification, rapid stroke triage, on-call stroke neurologists, immediate neuroimaging interpretation, and the innovative Pre-hospital Emergency Call and Location Identification feature. An interrupted time series analysis (ITSA) was used to assess the impact of ASCaM on DNT, comparing 9 months pre-intervention with 24 months post-intervention.Results: Data from 9,680 IVT-treated ischemic stroke patients were analyzed, including 2,401 in the pre-intervention phase and 7,279 post-intervention. The ITSA revealed a significant reduction in monthly DNT by −1.12 min and a level change of −5.727 min post-ASCaM implementation.Conclusion: The ASCaM initiative significantly reduced in-hospital delays for AIS patients, demonstrating its effectiveness as a comprehensive stroke care improvement strategy in urban settings. These findings highlight the potential of coordinated care interventions to enhance timely access to reperfusion therapies and overall stroke prognosis.
- 18 April 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1364952
Open AccessEffectiveness of the acute stroke care map program in reducing in-hospital delay for acute ischemic stroke in a Chinese urban area: an interrupted time series analysis
Background: Timely intravenous thrombolysis (IVT) is crucial for improving outcomes in acute ischemic stroke (AIS) patients. This study evaluates the effectiveness of the Acute Stroke Care Map (ASCaM) initiative in Shenyang, aimed at reducing door-to-needle times (DNT) and thus improving the timeliness of care for AIS patients.Methods: An retrospective cohort study was conducted from April 2019 to December 2021 in 30 hospitals participating in the ASCaM initiative in Shenyang. The ASCaM bundle included strategies such as EMS prenotification, rapid stroke triage, on-call stroke neurologists, immediate neuroimaging interpretation, and the innovative Pre-hospital Emergency Call and Location Identification feature. An interrupted time series analysis (ITSA) was used to assess the impact of ASCaM on DNT, comparing 9 months pre-intervention with 24 months post-intervention.Results: Data from 9,680 IVT-treated ischemic stroke patients were analyzed, including 2,401 in the pre-intervention phase and 7,279 post-intervention. The ITSA revealed a significant reduction in monthly DNT by −1.12 min and a level change of −5.727 min post-ASCaM implementation.Conclusion: The ASCaM initiative significantly reduced in-hospital delays for AIS patients, demonstrating its effectiveness as a comprehensive stroke care improvement strategy in urban settings. These findings highlight the potential of coordinated care interventions to enhance timely access to reperfusion therapies and overall stroke prognosis.
- Open Access
- 5 January 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1330959
Nomogram to predict 6-month mortality in acute ischemic stroke patients treated with endovascular treatment
Background: Acute Ischemic Stroke (AIS) presents significant challenges in evaluating the effectiveness of Endovascular Treatment (EVT). This study develops a novel prognostic model to predict 6-month mortality post-EVT, aiding in identifying patients likely to benefit less from this intervention, thus enhancing therapeutic decision-making.Methods: We employed a cohort of AIS patients from Shenyang First People’s Hospital, serving as the Validation set, to develop our model. LASSO regression was used for feature selection, followed by logistic regression to create a prognostic nomogram for predicting 6-month mortality post-EVT. The model’s performance was validated using a dataset from PLA Northern Theater Command General Hospital, assessing discriminative ability (C-index), calibration (calibration plot), and clinical utility (decision curve analysis). Statistical significance was set at p < 0.05.Results: The development cohort consisted of 219 patients. Six key predictors of 6-month mortality were identified: “Lack of Exercise” (OR, 4.792; 95% CI, 1.731–13.269), “Initial TICI Score 1” (OR, 1.334; 95% CI, 0.628–2.836), “MRS Score 5” (OR, 1.688; 95% CI, 0.754–3.78), “Neutrophil Percentage” (OR, 1.08; 95% CI, 1.042–1.121), “Onset Blood Sugar” (OR, 1.119; 95% CI, 1.007–1.245), and “Onset NIHSS Score” (OR, 1.074; 95% CI, 1.029–1.121). The nomogram demonstrated a high predictive capability with a C-index of 0.872 (95% CI, 0.830–0.911) in the development set and 0.830 (95% CI, 0.726–0.920) in the validation set.Conclusion: Our nomogram, incorporating factors such as Lack of Exercise, Initial TICI Score 1, MRS Score 5, Neutrophil Percentage, Onset Blood Sugar, and Onset NIHSS Score, provides a valuable tool for predicting 6-month mortality in AIS patients post-EVT. It offers potential to refine early clinical decision-making and optimize patient outcomes, reflecting a shift toward more individualized patient care.
- 5 January 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1330959
Open AccessNomogram to predict 6-month mortality in acute ischemic stroke patients treated with endovascular treatment
Background: Acute Ischemic Stroke (AIS) presents significant challenges in evaluating the effectiveness of Endovascular Treatment (EVT). This study develops a novel prognostic model to predict 6-month mortality post-EVT, aiding in identifying patients likely to benefit less from this intervention, thus enhancing therapeutic decision-making.Methods: We employed a cohort of AIS patients from Shenyang First People’s Hospital, serving as the Validation set, to develop our model. LASSO regression was used for feature selection, followed by logistic regression to create a prognostic nomogram for predicting 6-month mortality post-EVT. The model’s performance was validated using a dataset from PLA Northern Theater Command General Hospital, assessing discriminative ability (C-index), calibration (calibration plot), and clinical utility (decision curve analysis). Statistical significance was set at p < 0.05.Results: The development cohort consisted of 219 patients. Six key predictors of 6-month mortality were identified: “Lack of Exercise” (OR, 4.792; 95% CI, 1.731–13.269), “Initial TICI Score 1” (OR, 1.334; 95% CI, 0.628–2.836), “MRS Score 5” (OR, 1.688; 95% CI, 0.754–3.78), “Neutrophil Percentage” (OR, 1.08; 95% CI, 1.042–1.121), “Onset Blood Sugar” (OR, 1.119; 95% CI, 1.007–1.245), and “Onset NIHSS Score” (OR, 1.074; 95% CI, 1.029–1.121). The nomogram demonstrated a high predictive capability with a C-index of 0.872 (95% CI, 0.830–0.911) in the development set and 0.830 (95% CI, 0.726–0.920) in the validation set.Conclusion: Our nomogram, incorporating factors such as Lack of Exercise, Initial TICI Score 1, MRS Score 5, Neutrophil Percentage, Onset Blood Sugar, and Onset NIHSS Score, provides a valuable tool for predicting 6-month mortality in AIS patients post-EVT. It offers potential to refine early clinical decision-making and optimize patient outcomes, reflecting a shift toward more individualized patient care.
- Open Access
- 18 December 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 6 (6) , 526-536
miRNA‐137‐5p improves spatial memory and cognition in Alzheimer's mice by targeting ubiquitin‐specific peptidase 30
Background: Alzheimer's disease (AD) is a prevalent neurodegenerative disorder causing progressive dementia. Research suggests that microRNAs (miRNAs) could serve as biomarkers and therapeutic targets for AD. Reduced levels of miR‐137 have been observed in the brains of AD patients, but its specific role and downstream mechanisms remain unclear. This study sought to examine the therapeutic potential of miR‐137‐5p agomir in alleviating cognitive dysfunction induced in AD models and explore its potential mechanisms.Methods: This study utilized bioinformatic analysis and a dual‐luciferase reporter assay to investigate the relationship between miR‐137‐5p and ubiquitin‐specific peptidase 30 (USP30). In vitro experiments were conducted using SH‐SY5Y cells to assess the impact of miR‐137‐5p on Aβ1–42 neurotoxicity. In vivo experiments on AD mice evaluated the effects of miR‐137‐5p on cognition, Aβ1–42 deposition, Tau hyperphosphorylation, and neuronal apoptosis, as well as its influence on USP30 levels.Results: It was discovered that miR‐137‐5p mimics efficiently counteract Aβ1–42 neurotoxicity in SH‐SY5Y cells, a protective effect that is negated by USP30 overexpression. In vivo experiments demonstrated that miR‐137‐5p enhances the cognition and mobility of AD mice, significantly reducing Aβ1–42 deposition, Tau hyperphosphorylation, and neuronal apoptosis within the hippocampus and cortex regions. Mechanistically, miR‐137‐5p significantly suppresses USP30 levels in mice, though USP30 overexpression partially buffers against miR‐137‐5p‐induced AD symptom improvement.Conclusion: Our study proposes that miR‐137‐5p, by instigating the downregulation of USP30, has the potential to act as a novel and promising therapeutic target for AD.
- 18 December 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 6 (6) , 526-536
Open AccessmiRNA‐137‐5p improves spatial memory and cognition in Alzheimer's mice by targeting ubiquitin‐specific peptidase 30
Background: Alzheimer's disease (AD) is a prevalent neurodegenerative disorder causing progressive dementia. Research suggests that microRNAs (miRNAs) could serve as biomarkers and therapeutic targets for AD. Reduced levels of miR‐137 have been observed in the brains of AD patients, but its specific role and downstream mechanisms remain unclear. This study sought to examine the therapeutic potential of miR‐137‐5p agomir in alleviating cognitive dysfunction induced in AD models and explore its potential mechanisms.Methods: This study utilized bioinformatic analysis and a dual‐luciferase reporter assay to investigate the relationship between miR‐137‐5p and ubiquitin‐specific peptidase 30 (USP30). In vitro experiments were conducted using SH‐SY5Y cells to assess the impact of miR‐137‐5p on Aβ1–42 neurotoxicity. In vivo experiments on AD mice evaluated the effects of miR‐137‐5p on cognition, Aβ1–42 deposition, Tau hyperphosphorylation, and neuronal apoptosis, as well as its influence on USP30 levels.Results: It was discovered that miR‐137‐5p mimics efficiently counteract Aβ1–42 neurotoxicity in SH‐SY5Y cells, a protective effect that is negated by USP30 overexpression. In vivo experiments demonstrated that miR‐137‐5p enhances the cognition and mobility of AD mice, significantly reducing Aβ1–42 deposition, Tau hyperphosphorylation, and neuronal apoptosis within the hippocampus and cortex regions. Mechanistically, miR‐137‐5p significantly suppresses USP30 levels in mice, though USP30 overexpression partially buffers against miR‐137‐5p‐induced AD symptom improvement.Conclusion: Our study proposes that miR‐137‐5p, by instigating the downregulation of USP30, has the potential to act as a novel and promising therapeutic target for AD.
- Open Access
- 2 November 2023
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 28 (6) , 1-9
Neferine exerts anti‑inflammatory activity in BV‑2 microglial cells and protects mice with MPTP‑induced Parkinson's disease by inhibiting NF‑κB activation
Abnormal activation of microglia and the production of proinflammatory cytokines can lead to chronic neuroinflammation, which is an important pathological characteristic of Parkinson's disease (PD). Neferine is a chemical compound extracted from lotus seed which has previously been reported to exert protective effects on the development of several types of cancer, myocardial injury and hypoxic‑ischemic encephalopathy. However, its effect on microglial functions in neuroinflammation remains to be clarified. The present study used network pharmacology and screening in a lipopolysaccharide (LPS) model to demonstrate that neferine suppresses the production of inducible nitric oxide synthase, interleukin‑6 and tumor necrosis factor α in LPS‑treated BV‑2 cells. The working concentration of neferine did not exert cytotoxic effects on BV‑2 cells. Mechanistically, neferine attenuated inflammation by inhibiting the phosphorylation and nuclear translocation of the NF‑κB p65 subunit. In vivo, neferine protected mice from the inflammatory response in the substantia nigra and inhibited the development of nervous disorders in the 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine‑induced PD model. The present study demonstrated that neferine inhibited LPS‑mediated activation of microglia by inhibiting NF‑κB signaling. These findings may provide a new reference for the prevention and future treatment of PD.
- 2 November 2023
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 28 (6) , 1-9
Open AccessNeferine exerts anti‑inflammatory activity in BV‑2 microglial cells and protects mice with MPTP‑induced Parkinson's disease by inhibiting NF‑κB activation
Abnormal activation of microglia and the production of proinflammatory cytokines can lead to chronic neuroinflammation, which is an important pathological characteristic of Parkinson's disease (PD). Neferine is a chemical compound extracted from lotus seed which has previously been reported to exert protective effects on the development of several types of cancer, myocardial injury and hypoxic‑ischemic encephalopathy. However, its effect on microglial functions in neuroinflammation remains to be clarified. The present study used network pharmacology and screening in a lipopolysaccharide (LPS) model to demonstrate that neferine suppresses the production of inducible nitric oxide synthase, interleukin‑6 and tumor necrosis factor α in LPS‑treated BV‑2 cells. The working concentration of neferine did not exert cytotoxic effects on BV‑2 cells. Mechanistically, neferine attenuated inflammation by inhibiting the phosphorylation and nuclear translocation of the NF‑κB p65 subunit. In vivo, neferine protected mice from the inflammatory response in the substantia nigra and inhibited the development of nervous disorders in the 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine‑induced PD model. The present study demonstrated that neferine inhibited LPS‑mediated activation of microglia by inhibiting NF‑κB signaling. These findings may provide a new reference for the prevention and future treatment of PD.